CN114026093A - 用于治疗神经退行性疾病和线粒体疾病的组合物及其使用方法 - Google Patents
用于治疗神经退行性疾病和线粒体疾病的组合物及其使用方法 Download PDFInfo
- Publication number
- CN114026093A CN114026093A CN202080040787.8A CN202080040787A CN114026093A CN 114026093 A CN114026093 A CN 114026093A CN 202080040787 A CN202080040787 A CN 202080040787A CN 114026093 A CN114026093 A CN 114026093A
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- present
- membered
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962828995P | 2019-04-03 | 2019-04-03 | |
US62/828995 | 2019-04-03 | ||
US201962879794P | 2019-07-29 | 2019-07-29 | |
US62/879794 | 2019-07-29 | ||
US201962933632P | 2019-11-11 | 2019-11-11 | |
US62/933632 | 2019-11-11 | ||
PCT/US2020/026732 WO2020206363A1 (en) | 2019-04-03 | 2020-04-03 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114026093A true CN114026093A (zh) | 2022-02-08 |
Family
ID=72666280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080040787.8A Pending CN114026093A (zh) | 2019-04-03 | 2020-04-03 | 用于治疗神经退行性疾病和线粒体疾病的组合物及其使用方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220162215A1 (he) |
EP (1) | EP3947390A4 (he) |
JP (1) | JP2022527025A (he) |
KR (1) | KR20220004068A (he) |
CN (1) | CN114026093A (he) |
AU (1) | AU2020253561A1 (he) |
BR (1) | BR112021019802A2 (he) |
CA (1) | CA3135755A1 (he) |
IL (1) | IL286767A (he) |
MX (1) | MX2021012129A (he) |
WO (1) | WO2020206363A1 (he) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018237145A1 (en) | 2017-06-21 | 2018-12-27 | Mitokinin, Inc. | COMPOSITIONS AND METHODS USING THEM FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE |
WO2023023670A1 (en) * | 2021-08-20 | 2023-02-23 | Mitokinin, Inc. | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease |
WO2023023671A1 (en) * | 2021-08-20 | 2023-02-23 | Mitokinin, Inc. | Compositions and methods for treatment of neurodegenerative and mitochondrial disease |
WO2024040266A2 (en) * | 2022-08-19 | 2024-02-22 | Mitokinin, Inc. | Disubstituted benzoimidazole and indole analogs as modulators of pink1 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2429222C2 (ru) * | 2006-07-18 | 2011-09-20 | Астеллас Фарма Инк. | Аминоиндановое производное или его соль |
NZ710444A (en) * | 2013-02-11 | 2020-08-28 | Univ California | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy |
CA2939219C (en) * | 2014-02-11 | 2023-02-28 | Mitokinin Llc | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease |
WO2018237145A1 (en) * | 2017-06-21 | 2018-12-27 | Mitokinin, Inc. | COMPOSITIONS AND METHODS USING THEM FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE |
BR112022016614A2 (pt) * | 2020-02-21 | 2022-12-13 | Mitokinin Inc | Composições e métodos de uso dos mesmos para o tratamento de doenças neurodegenerativas e mitocondriais |
-
2020
- 2020-04-03 MX MX2021012129A patent/MX2021012129A/es unknown
- 2020-04-03 WO PCT/US2020/026732 patent/WO2020206363A1/en unknown
- 2020-04-03 US US17/601,372 patent/US20220162215A1/en active Pending
- 2020-04-03 JP JP2021560413A patent/JP2022527025A/ja active Pending
- 2020-04-03 EP EP20784272.5A patent/EP3947390A4/en active Pending
- 2020-04-03 KR KR1020217035783A patent/KR20220004068A/ko unknown
- 2020-04-03 CN CN202080040787.8A patent/CN114026093A/zh active Pending
- 2020-04-03 AU AU2020253561A patent/AU2020253561A1/en active Pending
- 2020-04-03 BR BR112021019802A patent/BR112021019802A2/pt unknown
- 2020-04-03 CA CA3135755A patent/CA3135755A1/en active Pending
-
2021
- 2021-09-29 IL IL286767A patent/IL286767A/he unknown
Also Published As
Publication number | Publication date |
---|---|
EP3947390A4 (en) | 2022-11-30 |
JP2022527025A (ja) | 2022-05-27 |
WO2020206363A1 (en) | 2020-10-08 |
IL286767A (he) | 2021-12-01 |
AU2020253561A1 (en) | 2021-12-02 |
US20220162215A1 (en) | 2022-05-26 |
MX2021012129A (es) | 2022-01-31 |
CA3135755A1 (en) | 2020-10-08 |
EP3947390A1 (en) | 2022-02-09 |
KR20220004068A (ko) | 2022-01-11 |
BR112021019802A2 (pt) | 2021-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114026093A (zh) | 用于治疗神经退行性疾病和线粒体疾病的组合物及其使用方法 | |
US10442782B2 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
CN104837825B (zh) | 鲁顿酪氨酸激酶抑制剂 | |
US10112922B2 (en) | Inhibitor of bruton's tyrosine kinase | |
US20200223851A1 (en) | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | |
US20100273769A1 (en) | Composition and method for the treatment of parkinson's disease | |
KR20140105598A (ko) | [1,2,4]트리아졸로피리딘 및 포스포디에스테라제 억제제로서의 이의 용도 | |
TW201516034A (zh) | 犬尿氨酸-3-單加氧酶抑制劑、藥物組合物及其使用方法 | |
CN114341145B (zh) | 化学化合物 | |
CN115427396A (zh) | 用于预防或治疗脂质代谢相关疾病的化合物 | |
TW201823222A (zh) | 化合物、醫藥組成物及其用途 | |
EA032129B1 (ru) | Пролекарство 1,1'-(1,6-диоксо-1,6-гександиил)бис-d-пролина | |
CN115515682B (zh) | 用于治疗神经退行性疾病和线粒体疾病的组合物及其使用方法 | |
WO2023023670A1 (en) | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | |
US20230026696A1 (en) | Trpv4 receptor ligands | |
CN113135907B (zh) | 一种提高α-微管蛋白乙酰化水平的化合物及其制备方法与应用 | |
WO2024040266A2 (en) | Disubstituted benzoimidazole and indole analogs as modulators of pink1 | |
CN113735825A (zh) | 1,2,3,6-四氢吡啶类化合物及其制备方法和用途 | |
JP2024520758A (ja) | Ttbk1の阻害剤 | |
JPWO2020059841A1 (ja) | プリオン病治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |